| Dr Lourdes Neugart, MD | |
|
4007 Diamond Ruby, Christiansted, VI 00820-4417 | |
| (340) 778-6311 | |
| Not Available |
| Full Name | Dr Lourdes Neugart |
|---|---|
| Gender | Female |
| Speciality | Psychiatry & Neurology - Child & Adolescent Psychiatry |
| Location | 4007 Diamond Ruby, Christiansted, Virgin Island |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104807064 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 1203 (Virgin Island) | Primary |
| 2084P0804X | Psychiatry & Neurology - Child & Adolescent Psychiatry | 1203 (Virgin Island) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lourdes Neugart, MD 1000 King St, Ste 4u, Christiansted, VI 00820-4995 Ph: (340) 719-2003 | Dr Lourdes Neugart, MD 4007 Diamond Ruby, Christiansted, VI 00820-4417 Ph: (340) 778-6311 |
News Archive
An increase in high-grade prostate cancer among men taking the drug finasteride is likely caused by an increased detection of cancers, and not by the development of more high-grade cancers, according to two studies published online September 11 in the Journal of the National Cancer Institute.
DNA Therapeutics, a private biopharmaceutical company developing DT01, a first-in-class clinical pan DNA repair inhibitor to treat tumors resistant to conventional treatments, will today present the results of the first-in-man phase 1/2a trial of DT01 in combination with radiation therapy in patients with cutaneous metastatic melanoma.
Genetic testing can uncover inherited genetic mutations, and could individualize cancer therapies, improve survival, manage cancer in loved ones and push the boundaries of precision medicine.
Cytori Therapeutics received expanded European approval (CE Mark) for its Celution System, a medical device that extracts and separates stem and regenerative cells from a patient's own fat tissue. The new indications include key medical applications such as breast reconstruction, repair of soft tissue defects, as well as the facilitation of healing certain types of wounds, such as those resulting from Crohn's disease. This broadens Cytori's ability to offer the Celution System to patients and hospitals and further supports the company's efforts to gain treatment reimbursement.
Vicept™ Therapeutics Inc., a privately held specialty biopharmaceutical company dedicated to developing the first effective topically applied therapy for erythema (facial redness) of rosacea, announced that it has secured $10 million to complete a total $16 million Series A financing. The Series A was led by Vivo Ventures, Sofinnova Ventures and Fidelity Biosciences.
› Verified 2 days ago
Makeda Naomi Jones, M.D Psychiatry & Neurology Medicare: May Accept Medicare Assignments Practice Location: 4007 Estate Diamond Ruby, Christiansted, VI 00820 Phone: 340-778-6311 |